RESEARCH-USE BIOSIMILAR ANTIBODY
Daratumumab
Monoclonal antibody · IgG1
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
TARGETCD38
YMonoclonal antibody
CATALOGSC-BS-643
CATALOG NUMBERSC-BS-643
MOLECULAR WEIGHTApprox. 145.26 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
Daratumumab is a recombinant research-use antibody directed against CD38.